The nation of Zimbabwe has declined a major American healthcare agreement valued at 367 million US dollars (272 million pounds) over five years over the United States' demand for confidential data.
The decision was revealed following a government memo dated December was disclosed, indicating that President Emmerson Mnangagwa deemed the deal was "skewed".
An official representative later stated that the US was seeking genetic material for scientific study and commercial gain while was unwilling to guarantee the benefits from future vaccines.
"We must now begin the challenging and unfortunate process of winding down our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had donated more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged continued talks to find a deal acceptable to all parties so the country's vital HIV treatment initiative can continue.
Wider Context
This rejection comes after a comparable case in neighbouring Kenya, where a high court suspended a related deal with the US following legal challenges were filed about the safety of citizens' health data.
Since returning to the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump claimed its expenditure was "wasteful" and his administration was seeking government-to-government agreements to boost transparency and responsibility.
As per reports, Sixteen nations in Africa have so far agreed to these new health pacts, representing more than $18.3bn in committed funds.
Specifics of the Declined Deal
This assistance for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment through American-funded programmes," the Ambassador said.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, with no corresponding assurance of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that shared data," Mangwana explained.
"In essence, our nation would provide the raw materials for scientific discovery without any certainty that the resulting innovations would be available to our citizens if a new pandemic emerge."
National Interest and International Frameworks
He also said that the US's withdrawal from the global health body and its pursuit of one-on-one deals were upending frameworks previously set up through the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to deal with potential global health emergencies.
"This system is intended to guarantee that when a country contributes its information, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to create them."
The government's concerns over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We are open to ongoing dialogue with our US partners on how subsequent collaboration might be arranged in a way that honours the sovereignty and dignity of each country."
Medical Community Reaction
A leading public health body stated it recognised the official position, but urged that talks must proceed given that much of the country's HIV programmes were funded by foreign aid.
"In cases where specific concerns arise, such as those relating to information security or implementation frameworks, these can frequently be addressed via technical clarification and negotiated safeguards," it added.
The halted deal emphasises the ongoing debate between accepting crucial international aid and protecting local interests in an ever more data-driven world.